NEW YORK, Sept. 25, 2012 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Peregrine Pharmaceuticals, Inc. ("Peregrine" or the "Company") (NasdaqCM: PPHM -News), concerning potential violations of federal securities laws.
Shares of Peregrine fell over 75% after the company released a statement on Monday disclosing that major discrepancies were discovered between patient sample test results and patient treatment code. The discrepancy was made while reviewing trial data in preparation for a meeting with the U.S. Food and Drug Administration. According Peregrine, any data released on or before September 7, 2012, from its Phase II bavituximab trial in patients with second-line non-small cell lung cancer or any presentations or other documents related to this Phase II trial could be inaccurate.
If you are aware of any facts relating to this investigation, or purchased shares of Peregrine, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.Contact:Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Eitan Kimelman, 212-697-6484 email@example.com SOURCE Bronstein, Gewirtz & Grossman, LLC